Gaudium IVF And Women Health Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹-2(-2.53%)
Premium (ELP)
Having completed its public offering, Gaudium IVF And Women Health Limited's is now listed and trading on the NSE, BSE exchange as of Feb 27, 2026. The IPO raised cumulative capital of 2,08,86,200 Shares, including 1,13,92,500 Shares in primary capital infusion and ₹75.00 Cr in secondary market transactions.
The IPO was conducted with a price range of ₹75 to ₹79 and minimum investment requirement of 189 shares. subscription activity between Feb 20, 2026 and Feb 24, 2026 reflected market assessment of the offering's valuation and prospects.
The allotment process finalized on Feb 25, 2026 distributed equity ownership to successful bidders. The listing established a transparent market mechanism for share trading, price discovery, and investor participation in the company's future growth.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Founded in March 2015, Gaudium IVF and Women Health Limited specializes in In Vitro Fertilization (IVF) and women’s healthcare services across India, operating through a hub-and-spoke model with seven hubs and twenty-eight spokes. The company collaborates with Infertility Experts to promote awareness of Assisted Reproductive Technology (ART) and IVF treatments. Serving patients from countries like Canada, the UK, the USA, Kenya, South Africa, and Oman, Gaudium has centres in key cities such as Delhi, Mumbai, Ludhiana, Srinagar, Patna, and Bangalore. It offers advanced fertility treatments including IVF, ICSI, IUI, ovulation induction, and male infertility solutions, along with specialized care for PCOD/PCOS, endometriosis, and high-risk pregnancies.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Patient-Centric Care: Focuses on personalized fertility and women’s healthcare solutions.
- Experienced Medical Team: Skilled fertility specialists drive strong clinical outcomes.
- Advanced Lab Infrastructure: Equipped with next-gen INTEGRA Ti technology for high-precision procedures.
- Healthcare & Legal Risk: Fertility treatments face strict medical, regulatory, and reputational scrutiny.
- Dependence on Medical Professionals: Difficulty in attracting or retaining specialists may affect performance.
- Brand Reputation Risk: Negative publicity or allegations could impact patient trust and business growth.
- Dr. Manika Khanna
- Dr. Peeyush Khanna
- Vishad Khanna
Gaudium IVF And Women Health Limited
Bigshare Services Private Limited